Study Data Release, Dividends and Shares Repurchases, Committee Recommendations, New Partners, and Upcoming Conferences - Research Reports on Celgene, Abbott, Actavis, UnitedHealth and Bristol-Myers
Editor Note: For more information about this release, please scroll to bottom.
NEW YORK, September 16, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Celgene Corporation (NASDAQ: CELG), Abbott Laboratories (NYSE: ABT), Actavis plc (NYSE: ACT), UnitedHealth Group Inc. (NYSE: UNH) and Bristol-Myers Squibb Co. (NYSE: BMY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6496-100free.
--
Celgene Corporation Research Reports
On September 4, 2014, Celgene Corporation (Celgene) announced that the data from FIRST (MM-020/IFM 07-01)-an open-label phase III randomized study of continuous REVLIMID (lenalidomide) in combination with dexamethasone in patients newly diagnosed with multiple myeloma (NDMM) who are not candidates for stem cell transplant-was published in the September 4, 2014 issue of the New England Journal of Medicine. Celgene informed that the findings of the study demonstrated that at a median follow-up of 37 months among surviving patients, the median progression-free survival was 25.5 months with continuous oral lenalidomide plus low-dose dexamethasone (Rd), 20.7 months with a fixed course of oral lenalidomide plus low-dose dexamethasone (Rd18) and 21.2 months with melphalan, prednisone and thalidomide (MPT). The full research reports on Celgene are available to download free of charge at:
http://www.analystsreview.com/Sep-16-2014/CELG/report.pdf
--
Abbott Laboratories Research Reports
On September 11, 2014, Abbott Laboratories (Abbott) announced that its Board of Directors has authorized shares repurchase of up to $3 billion of the Company's common shares. According to Abbott, this new authorization is in addition to the $511 million unused portion of the previous program that was announced in June 2013. In addition the Board has declared a quarterly common dividend of $0.22 per share, payable on November 15, 2014 to shareholders of record at the close of business on October 15, 2014. The full research reports on Abbott are available to download free of charge at:
http://www.analystsreview.com/Sep-16-2014/ABT/report.pdf
--
Actavis plc Research Reports
On September 9, 2014, Actavis plc (Actavis) announced that the U.S. Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of Actavis' New Drug Application (NDA) for the fixed-dose combination of nebivolol and valsartan for the treatment of hypertension. Actavis informed that six out of ten members voted against the approval. Actavis stated that the committee's recommendation is not binding on the FDA, which makes the final decision regarding approval. The Company expects FDA action on its NDA for the fixed-dose combination of nebivolol and valsartan by Q4 2014. David Nicholson, Senior Vice President, Global Brands Research and Development, Actavis, said, "We remain confident in the safety and efficacy of the combination of these two widely used and well-tolerated treatments, and we look forward to working with the FDA as it completes its review." The full research reports on Actavis are available to download free of charge at:
http://www.analystsreview.com/Sep-16-2014/ACT/report.pdf
--
UnitedHealth Group Inc. Research Reports
On September 9, 2014, UnitedHealth Group Inc. (UnitedHealth) reported that its subsidiary Optum's Optum Labs - the collaborative research and innovation center co-founded by Optum and Mayo Clinic, has added four new partners committed to improving the quality and value of patient care. UnitedHealth informed that the new partners to join Optum Labs are: Harvard Medical School Department of Health Care Policy, Medica Research Institute, Merck, and University of Maryland, Baltimore. In addition, Optum Labs previously announced relationships with founding consumer advocate organization AARP, the American Medical Group Association (AMGA), Boston Scientific, Boston University School of Public Health, Lehigh Valley Health Network, Pfizer Inc., Rensselaer Polytechnic Institute, Tufts Medical Center, and the University of Minnesota School of Nursing. Paul Bleicher, M.D., Ph.D., CEO of Optum Labs, said, "Our growing base of partners enables Optum Labs to expand into additional areas of health care research, paving the way for new initiatives that can be directly translated to improvements in patient care. We are excited by the diverse perspectives our partners are bringing to a growing number of research studies under way." The full research reports on UnitedHealth are available to download free of charge at:
http://www.analystsreview.com/Sep-16-2014/UNH/report.pdf
--
Bristol-Myers Squibb Co. Research Reports
On September 11, 2014, Bristol-Myers Squibb Co. (Bristol-Myers) announced that its Senior Vice President, Public Affairs and Investor Relations, John Elicker will present at the upcoming Bank of America Merrill Lynch Global Health Care Conference on September 18, 2014, at 9:45 a.m. BST (4:45 a.m. EDT) in London. Bristol-Myers informed that the live webcast of the presentation will be available on its official website. The Company added that the materials related to the presentation will be available at the same location. The full research reports on Bristol-Myers are available to download free of charge at:
http://www.analystsreview.com/Sep-16-2014/BMY/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article